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Abstract
Introduction Self-report instruments such as the Impact of
Cancer (IOC) are designed to measure quality of life (QOL)
impacts that cancer survivors attribute to their cancer
experience. Generalizability of QOL findings across dis-
tinct diagnostic categories of survivors is untested. We
compare measurement of the impact of cancer using the
IOC instrument in breast cancer (BC) survivors (n=1,188)
and non-Hodgkin lymphoma (NHL) survivors (n=652).
Methods A registry-based sample of NHL survivors com-
pleted the IOC questionnaire and the FACT-G, FACT-LYM,
Medical Outcomes Study (MOS) SF-36, Post-Traumatic
Stress Disorder Checklist-Civilian Version, Post-Traumatic
Growth Inventory and MOS Social Support scales. IOC
responses of the NHL survivors were subjected to de novo
scaling to identify impact domains for comparison to IOC
version 2 (IOCv2) domains, which were previously
developed based on BC survivor responses. Concurrent
validity was assessed by correlating the IOCv2 scales with
the other measures. IOCv2 scores were compared between
the BC and NHL survivor samples.
Results The BC and NHL survivors exhibited similar
impact domains and had factor structures that were largely
congruent. The concurrent validity analysis revealed pat-
terns of association that supported the interpretation and
validity of the IOCv2 scales. Differences in IOCv2 scores
between the BC and NHL groups suggested differential
impacts in distinct survivor groups that could be detected
using the IOCv2.
Conclusion The results suggest that the IOCv2 measures
common and important survivor concerns and support its
generalizability to the broader long-term cancer survivor
population.
Implications for Cancer Survivors Instruments such as the
IOCv2 can provide valid assessment of QOL impacts in
long-term cancer survivors, facilitating the characteriza-
tion of these impacts and development of appropriate
interventions.
Keywords Breast cancer.Cancer survivor.
Non-Hodgkin lymphoma.Qualityof life
Introduction
There is a large and growing population of cancer survivors
[1], with an expanding literature documenting impacts of
cancer among survivors across physical, psychological,
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research on health-related quality of life (HRQOL) in this
growing at-risk population was recently highlighted by the
Institute of Medicine [7]. Valid assessment of HRQOL in
cancer survivors is a prerequisite for characterizing and
monitoring these impacts and developing appropriate
interventions. However, standardized measures of HRQOL
often fail to address the unique concerns reported by long-
term survivors. For example, many survivors experience
health and body image concerns that are specifically
cancer-related [8–10]. In addition, research with cancer
patients has increasingly recognized that a large proportion
report positive life changes or personal growth as a result
of their illness, a construct referred to as benefit finding
[11–16]. Generic HRQOL measures are generally not
designed to capture these domains. This has created a need
to develop targeted instruments measuring domains important
to the well-being of cancer survivors [17–20].
Several instruments have been developed specifically to
measure the concerns of long-term cancer survivors. An
early example is the Quality of Life-Cancer Survivors
(QOL-CS) scale [21], an instrument adapted from existing
broad-based HRQOL instruments composed predominantly
of generic items. The Quality of Life in Adult Cancer
Survivors (QLACS) scale [22, 23] is a more recent
instrument covering five cancer-specific domains (Financial
Problems, Benefits, Distress-Family, Appearance, Distress-
Recurrence) and seven generic domains (Negative Feelings,
Positive Feelings, Cognitive Problems, Pain, Sexual Interest,
Energy/Fatigue, Sexual Function, Social Avoidance). Tar-
geted, construct-specific instruments for cancer survivors
have also been developed. For example, the Breast Cancer
Prevention Trial (BCPT) Symptom Checklist assesses phys-
ical effects of medical intervention to prevent and treat breast
cancer [24, 25], and several scales measure fear of cancer
recurrence [26, 27]. Construct-specific scales such as these
are generally designed to serve as adjuncts to, or modules in,
other HRQOL instruments.
With the goal of developing a comprehensive instrument
specifically designed to measure HRQOL impacts that
long-term survivors ascribe to their cancer experience and
with funding from the National Cancer Institute’s Office of
Cancer Survivorship, members of our group and others
have developed the Impact of Cancer (IOC) scale [28–30].
The IOC measures both negative impacts and the positive
life changes reported by many survivors, such as a finding
of meaning or purpose, which generic HRQOL instruments
are generally not designed to capture [31–33]. The IOC was
developed through a standard psychometric approach
(qualitative interviews with long-term survivors for item
generation followed by item reduction, cognitive testing
and additional reduction to a pool of 81 items), leading to
an initial scale identification using data from 193 survivors
of breast, prostate, colorectal and lymphatic cancers [28,
29]. Recently, more comprehensive scaling using data from
1,188 breast cancer (BC) survivors was conducted [30].
This effort included de novo scaling of the 81-item pool,
split-sample cross-validation and evaluation of internal
consistency and construct and concurrent validity, yielding
the Impact of Cancer version 2 (IOCv2) scales (instrument
available from the first author) [30], with 37 items
composing positive and negative summary scales (includ-
ing eight subscales) and 10 items measuring employment
and relationship concerns.
To be widely useful, instruments measuring HRQOL in
cancer survivors must be valid across different cancer
diagnoses. The IOCv2 scales demonstrated excellent
internal consistency and validity, but proof of their
generalizability is limited due to testing only in female
BC survivors who were 5–10 years post-diagnosis. Would
these same scales be confirmed among survivors with a
different cancer diagnosis, gender distribution and treat-
ment trajectory? In particular, would another survivor group
identify similar impact domains and have scale scores that
are equally valid measurements of the underlying constructs?
Investigation of these issues is necessary to establish reliable
and well-validated scales to measure the psychosocial impacts
of cancer across the spectrum of diagnoses and survivorship
stages. This study was undertaken to examine the reliability
and validity of the IOCv2 scales in an independent sample of
652 disease-free non-Hodgkin lymphoma (NHL) survivors,
and to compare results for the BC and NHL survivors to
evaluate the generalizability of the IOCv2 across survivor
samples.
Participants and methods
Participants
NHL survivors were identified through the Duke University
and University of North Carolina at Chapel Hill Lineberger
tumor registries in November 2004 as previously described
[34]. Patients were eligible if diagnosed with NHL,≥19 years
old at diagnosis, and ≥2 years post-diagnosis. Prospective
participants were mailed a self-administered survey that
included the 81 IOC items and other measures described
below. Of the 1195 eligible survivors who were assumed to
have received a mailed survey, 886 (74%) returned survey
materials. Participating survivors were less frequently African
American and older at diagnosis and study enrollment [34].
Patients reporting active disease or with unknown recurrence
status (n=2 3 4 )w e r ee x c l u d e dt ol i m i tt h ea n a l y s i st od i s e a s e -
free survivors.
The BC survivors were members of the Life After
Cancer Epidemiology cohort [35], recruited primarily from
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registries. Patients were eligible if they were diagnosed at
age 18–79 with a primary breast cancer (Stage 1≥1 cm, 2,
2A) within 39 months of enrollment, had no history of
other cancer within five years of enrollment, had completed
treatment (except for adjuvant hormonal therapy), and were
recurrence-free at enrollment. Of 5656 women presumed to
meet the LACE eligibility criteria, 2614 (46%) agreed to
participate. Responders were closer to their diagnosis date
and older than nonresponders but did not differ in severity
of cancer or treatment [35]. Subsequent review resulted in
293 exclusions. Participants completed the 81 IOC items as
part of a mailed self-administered resurvey April 2006–
January 2007. The IOC questionnaire was returned by 1286
of 1805 women (71%). Respondents were older at
diagnosis and enrollment, more likely to be white, and
had higher levels of education than nonrespondents [30].
Women with recurrent or new primary disease or unknown
status in this regard were excluded from our study sample
(n=98).
Institutional review board approval was obtained at all
institutions participating in the study and written informed
consent was obtained from each participant.
Measures
The full IOC questionnaire [28] comprises 81 items that
present statements regarding specific impacts of cancer to
which respondents indicate their level of agreement from 1
(strongly disagree) to 5 (strongly agree). Seventy items
apply to all survivors, 3 to currently employed respondents,
4 to respondents not currently partnered, and 4 to currently
partnered respondents. The IOCv2, a scaled instrument
using 47 of these items [30] is provided in the appendix
online.
The Functional Assessment of Cancer Therapy: General
(FACT-G) is a general HRQOLmeasureforpatientsreceiving
cancer treatment that yields a total score and subscales for
physical, functional, social/family and emotional well-being
[36]. FACT-LYM is a diagnosis-specific measure for NHL
patients [37].
The Medical Outcomes Study (MOS) SF-36 is a generic
patient-assessed health outcome measure yielding eight sub-
scales and physical and mental health summary scores [38].
The Post-Traumatic Stress Disorder Checklist–Civilian
Version (PCL-C) presents a self-report symptom checklist
that mirrors criteria for a formal diagnosis of post-traumatic
stress disorder [39, 40]. Instructions were modified to key
symptoms to lymphoma diagnosis and treatment as the
stressor of interest. Survivors rated 17 symptoms on intensity
from 1 (not at all) to 5 (extremely bothersome).
The Posttraumatic Growth Inventory (PTGI) assesses
positive outcomes reported by persons who have experienced
traumatic events and yields a total scale and five subscales
[41, 42].
The MOS Social Support Score assesses perceived
availability of social support, with a total scale and four
subscales pertaining to particular functions served by
interpersonal relationships [43].
Statistical analysis
The goals of the analyses were to perform an independent
psychometric evaluation of the IOC in the NHL sample and
to compare these results with those from the BC survivors.
First we conducted a de novo exploratory factor analysis on
the NHL survivor data using the 70 IOC items applicable to
all survivors, closely mirroring the scaling process previ-
ously used for the BC survivor sample [30]. Employment
and relationship items, which were scaled separately for the
BC sample, were also not included in this factor analysis
for the NHL sample. Factors were extracted using principal
components, the number of factors was selected using
eigenvalue>1 and scree plots, and promax rotation was
performed. After an initial factor analysis, items with factor
loadings<0.50 or not associated with a clearly identifiable
factor were dropped and the factor analysis was repeated to
produce a set of factors for comparison to the IOCv2 scales
obtained from the BC survivor analysis.
Next, we assessed whether the 37-item, 8-factor structure
of the IOCv2 positive and negative subscales exhibited by
the BC survivors was reproduced in the NHL survivor
sample using the targeted rotation method [44], which
compares the factor structure of a second sample (NHL
survivors) to a reference structure (BC survivors) by
extracting the hypothesized number of factors from the
second sample and calculating congruence coefficients,
which compare two sets of factor loadings in terms of
pattern and magnitude [44, 45].
Concurrent validity was evaluated by forming a priori
hypotheses about patterns of association and correlating the
IOCv2 scores with HRQOL (FACT, SF-36), PCL-C, PTGI
and Social Support scores. We hypothesized that the IOCv2
positive scales would be uncorrelated with the HRQOL
measures (which are not designed to capture positive
impacts) and positively correlated with the PTGI total and
subscales (which similarly measure personal growth asso-
ciated with a traumatic event). We expected an overall
pattern of moderate to strong correlation between the
IOCv2 negative scales and the HRQOL scales. We
hypothesized that the IOCv2 negative summary score
would be strongly correlated with aggregate measures of
negative impacts (FACT-G, FACT-LYM, SF-36 Physical
and Mental, PCL-C Total). We further hypothesized that
IOCv2 Body Change Concerns would be correlated with
scales measuring physical limitations, that IOCv2 Life
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functional limitations, and that IOCv2 Worry would be
correlated with FACT-G Emotional. We expected IOCv2
Employment Concerns to be moderately correlated with
HRQOL measures, and IOCv2 Relationship Concerns to be
negatively correlated with the FACT-G Social/Family and
Social Support scales.
When evaluating the quantitative significance of correla-
tions, we considered |r|<0.30 to indicate weak association,
0.30≤|r|<0.45 moderate, 0.45≤|r|<0.60 substantial and |r|≥
0.60 high [46]. We used P<0.005 for statistical significance
to account for the large sample size and multiple compar-
isons. All P-values and significance tests were two-sided.
Internal consistency reliability was measured using
Cronbach’s alpha [47]. We obtained mean scale scores
adjusted for age and years since diagnosis and tested for
differences in adjusted means using the SAS GLM
procedure. All analyses were conducted using SAS 9.1.
Results
Sample characteristics
The NHL group included similar numbers of men and women,
in contrast to the exclusively female BC survivors (Table 1).
Comparisons revealed significant differences between the
groups on all characteristics except education and income. On
average, the BC survivors were diagnosed at an older age and
were older at time of survey. Mean interval since diagnosis
was longer in the NHL survivors, who also had a broader
range of interval. The NHL survivors reported about one
more comorbidity on average than the BC group. Despite
statistically significant differences in race/ethnicity and marital
status, both groups were predominantly white and partnered.
De novo factor analysis
Table 2 presents results of the de novo exploratory factor
analysis of the IOC items for the NHL sample. Eight
domains emerged that were largely congruent with the eight
domains found in the IOCv2 scaling on the BC survivor
data. In particular, factors for Altruism/Empathy, Health
Awareness, Meaning of Cancer, Positive Self-Evaluation,
Appearance Concerns and Worry emerged that were either
identical to the IOCv2 in item content or differed by one
item. Whereas Body Change Concerns and Life Interfer-
ences emerged as distinct factors in the BC survivor data,
these two constructs emerged as a single factor in the NHL
sample. However, all Body Change Concern items in the
IOCv2 were also identified in the NHL sample, and five of
the seven life interference items in the IOCv2 also appeared
in the NHL sample.
The NHL analysis also yielded a three-item scale that
did not emerge in the BC sample but which was identical to
the Positive Outlook subscale identified in the first scaling
of the IOC in a sample of 193 survivors of breast,
colorectal, lymphatic and prostate cancers [28].
Reproducibility of factor structure
The 8-factor structure of the IOCv2 positive and negative
subscales exhibited by the BC survivor sample was well-
reproduced in the NHL survivor sample, as evidenced by
high congruence coefficients (Table 3). All item congruences
exceeded 0.90 with the exception of two items on the Life
Interferences subscale. Despite these lower values, the factor
congruence for Life Interferences was 0.88. Other factor
congruences ranged from 0.95–0.98.
Concurrent validity
Table 4 summarizes the NHL survivor scores on the FACT,
SF-36, PCL-C, PTGI and Social Support scales, and presents
the correlations of these scores with the IOCv2 positive
scales. Table 5 presents correlations with the IOCv2 negative
and employment and relationship concern scales.
The observed patterns of association were largely
consistent with prior hypotheses. There was a striking lack
of correlation between the IOCv2 positive scales and the
FACT-G, FACT-LYM and SF-36, supporting the distinctive
content of the IOCv2 positive domains from these scales.
The PCL-C and Social Support scales were also uncorre-
lated with the IOCv2 positive scales, indicating that the
IOCv2 positive constructs were unrelated to either post-
traumatic stress symptoms or perceived availability of
particular relationships. Strong or substantial correlations
were observed between the PTGI and IOCv2 Altruism/
Empathy, Meaning of Cancer and Positive Self-Evaluation,
as well as the IOCv2 Positive Impact Summary, as expected
due to their similar goal of measuring personal growth
ascribed to a traumatic experience. There was lesser
correlation with IOCv2 Health Awareness, consistent with
the lack of health focus of the PTGI.
As expected, there was an overall pattern of moderate to
strong correlation between the IOCv2 negative scales and
the FACT-G, FACT-LYM and SF-36, with higher correla-
tions evident for the FACT-G and FACT-LYM, which are
cancer-specific, than for the SF-36, which is not. The
strongest correlation was between the IOCv2 Negative
Impact Summary score and the FACT-LYM, which is
specifically designed to measure negative HRQOL symptoms
in lymphoma survivors. The IOCv2 Negative Impact
Summary score was also correlated with the other aggregate
measures of negative impacts (FACT-G, SF-36 Physical and
Mental, PCL-C). Particularlystriking werestrongcorrelations
48 J Cancer Surviv (2010) 4:45–58Table 1 Characteristics of the non-Hodgkin lymphoma and breast cancer survivor samples
NHL survivors BC survivors p
Characteristic No. % No. %
Total No. of respondents 652 1188
Sex <0.001
Male 329 50
Female 323 50 1188 100
Race <0.001
White 565 87 958 83
African American 51 8 36 3
Hispanic 9 1 58 5
Asian/Pacific Islander 2 0.3 60 5
Other/more than one 25 4 46 4
Marital status <0.001
Married/living with partner 518 80 799 68
Widowed/divorced/separated/single 133 20 384 32
Income 0.769
<$60,000 331 56 612 56
≥$60,000 255 44 486 44
Education 0.163
High school or less 179 28 290 24
Some college 205 32 423 36
College graduate or higher 259 40 471 40
Employment 0.015
Employed 263 41 412 35
Retired/unemployed 381 59 763 65
Age, years <0.001
25–49 115 18 63 5
50–64 235 36 474 40
65–79 237 36 536 45
≥80 65 10 115 10
Mean±SD 62.7±13.5 66.3±10.1 <0.001
Range 25–91 34–89
Age at diagnosis, years <0.001
19–49 280 43 245 21
50–64 249 38 545 46
65–86 123 19 398 34
Mean±SD 51.9±14.2 58.8±10.1 <0.001
Range 19–86 25–80
Time since diagnosis, years <0.001
2–5 151 23
5–10 236 36 1188 100
10–20 181 28
≥20 84 13
Mean±SD 10.8±7.5 7.4±0.9 <0.001
Range 2.5–43.6 5.3–9.9
Number of comorbidities <0.001
0 72 11 270 23
1–2 251 39 548 47
3–5 247 38 295 25
≥67 6 1 2 5 9 5
Mean±SD 2.9±2.1 2.0±1.9 <0.001
Range 0–11 0–20
BC breast cancer; NHL non-Hodgkin lymphoma; SD standard deviation.
Tests for differences between the NHL and BC groups were conducted using two-sample t tests, chi-square tests and Fisher exact tests.
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Factor loadings from exploratory
factor analyses
BC survivors NHL survivors
Altruism/Empathy
Having had cancer has made me more willing to help others 0.86 0.89
Because I had cancer I am more understanding of what other people feel 0.80 0.84
I feel a special bond with people with cancer 0.77 0.83
I feel I should give something back to others 0.76 0.86
I place a higher value on my relationships with family or friends than I did before having had cancer 0.63
I learned something about myself because of having had cancer 0.61
Health awareness
Having had cancer has made me more concerned about my health 0.87 0.80
I do not take my body for granted since I had cancer 0.78 0.69
I am more aware of physical problems or changes 0.75 0.76
Having had cancer has made me take better care of myself 0.70 0.62
Meaning of cancer
Because of cancer I have more confidence in myself 0.90 0.84
Having had cancer has given me direction in life 0.86 0.83
Because of cancer I have become better about expressing what I want 0.85 0.85
Because of having had cancer I feel that I have more control of my life 0.72 0.80
Having had cancer turned into a reason to make changes in my life 0.65 0.74
Positive self-evaluation
I consider myself to be a cancer survivor 0.80 0.70
I feel a sense of pride or accomplishment from surviving cancer 0.91 0.66
I feel that I am a role model 0.67 0.58
I learned something about myself because of having had cancer 0.71
Positive outlook
Having had cancer has made me realize that time is precious 0.82
I learned something about life because of having had cancer 0.71
Having had cancer has strengthened my religious faith or sense of spirituality 0.62
Appearance concerns
I worry about how my body looks 0.69 0.82
I feel disfigured 0.86 0.88
I sometimes wear clothing to cover parts of my body 0.82 0.86
Body change concerns*
I am bothered that my body cannot do what it could before 0.94 0.84
I am concerned that my energy has not returned 0.91 0.82
Having had cancer has made me feel old. 0.59 0.76
Life interferences*
Having had cancer has made me feel alone 0.78 0.70
I feel like cancer runs my life 0.74 0.74
Having had cancer has made me feel like some people do not understand me 0.74 0.67
I feel guilty today for not having been available to my family 0.64 0.60
Ongoing symptoms interfere with my life. 0.58 0.84
Uncertainty about my future affects my decisions to make plans 0.79
Having had cancer keeps me from doing activities I enjoy 0.77
My life would be better today if I had not had cancer 0.75
Having to pay attention to my physical health interferes with my life. 0.69
Having had cancer has motivated me to make plans for dying (get my affairs in order) 0.67
50 J Cancer Surviv (2010) 4:45–58between the IOCv2 negative scales and the PCL-C. These
correlations are consistent with the parallel approaches of the
PCL-C and IOCv2, which both focus on concerns that
respondents attribute specifically to their cancer experience.
The IOCv2 negative scales were uncorrelated with the PTGI,
and weakly inversely correlated with Social Support.
With regard to the negative subscales, IOCv2 Appearance
Concerns showed diffuse connection with various physical
and emotional scales. IOCv2 Body Change Concerns was
correlated with scales measuring physical concerns, and also
correlated with mental and emotional scales; this is consistent
with the item content of Body Change Concerns, which
focuses on emotional reactions to physical changes. IOCv2
Life Interferences showed correlation with each of the FACT-
G subscales and SF-36 Mental, and was most strongly
correlated with FACT-LYM and PCL-C Total. IOCv2 Worry
w a sm o s ts t r o n g l yc o r r e l a t e dw i t hF A C T - GE m o t i o n a l ,w h i c h
contains items pertaining to worry. IOCv2 Employment
Concerns showed correlation with the FACT-G, SF-36 and
PCL-C, suggesting more employment concerns among
respondents with poorer overall HRQOL. The IOCv2
Relationship Concerns subscales were inversely correlated
with the Social Support scales, and also correlated with the
FACT-G, FACT-LYM, SF-36 Mental and PCL-C scales,
suggesting more relationship concerns among respondents
with poorer HRQOL.
Comparison of IOCv2 scores
Table 6 provides Cronbach’s alpha for the IOCv2 scales for
both survivor groups. All alphas for the BC group exceeded
0.75. All alphas for the NHL group exceeded 0.70 with the
exception of Relationship Concerns (non-partnered), which
had alpha=0.59. Many authorities consider alpha>0.70
acceptable[48], while others accept alpha>0.50 or 0.60 [49].
For both groups, scores on all IOCv2 scales ranged over
all or most of the possible 1 to 5 range, suggesting good
potential for sensitivity and discrimination.
Table 6 compares unadjusted and adjusted mean IOCv2
scores for the BC and NHL survivors, with the adjustment
accounting for differences in age and years since diagnosis.
To account for gender differences, adjusted means for the BC
sample and women in the NHL sample are also compared.
Unadjusted and adjusted mean scores for both groups on
the Positive Impact Summary Scale were in the “agree”
range, indicating endorsement of positive impacts due to
cancer in both groups. A marginally significant difference
in unadjusted mean scores between the BC and NHL
survivors became non-significant after adjusting for age and
time since diagnosis. However, there were differences
between the groups on positive subscales that remained after
adjustment. In particular, the NHL survivors had higher mean
scores on Altruism/Empathy and lower scores on Meaning of
Cancer. Differences on the latter were partially accounted for
by gender differences, with NHL men scoring lower on
Meaning of Cancer than NHL women on average.
Mean scores on the Negative Impact Summary Scale were
in the “disagree” range and differed between the groups in
adjusted and unadjusted analyses, with the BC survivors
reporting more negative impacts. Mean scores on Appearance
Concerns were a full point higher among the BC survivors.
DifferencesonBodyChangeConcerns,LifeInterferencesand
Worry were non-significant after adjustment.
The BC survivors reported higher levels of relationship
concerns, both for partnered and unpartnered respondents,
with these differences remaining significant after adjustment.
Table 2 (continued)
Factor loadings from exploratory
factor analyses
BC survivors NHL survivors
I have financial problems that are related to having had cancer. 0.59
Worry
Having had cancer makes me feel uncertain about my health 0.88 0.87
I worry about the future 0.82 0.87
Having had cancer makes me feel unsure about the future 0.81 0.83
I worry about cancer coming back or getting another cancer 0.81 0.85
New symptoms make me worry about cancer coming back 0.77 0.83
I worry about my health 0.76 0.72
I feel like time in my life in running out 0.59 0.57
I am afraid to die. 0.67
BC breast cancer; NHL non-Hodgkin lymphoma
Body change concerns and life interferences emerged as a single domain in the factor analysis on the NHL sample.
J Cancer Surviv (2010) 4:45–58 51Table 3 Results of reproducibility analysis comparing factor structure for non-Hodgkin lymphoma and breast cancer survivor samples
IOCv2 subscales and items Factor Congruence Item Congruence
Altruism/Empathy 0.96
Having had cancer has made me more willing to help others 0.99
Because I had cancer I am more understanding of what others feel 0.96
I feel a special bond with people with cancer 0.98
I feel I should give something back to others 0.98
Health awareness 0.95
Having had cancer has made me more concerned about my health. 1.00
I do not take my body for granted since I had cancer. 0.94
I am more aware of physical problems or changes. 0.99
Having had cancer has made me take better care of myself. 0.96
Meaning of cancer 0.98
Because of cancer I have more confidence in myself 0.99
Having had cancer has given me direction in life 0.99
Because of cancer I have become better about expressing what I want 0.99
Because of having had cancer I feel that I have more control of my life 0.98
Having had cancer turned into a reason to make changes in my life 0.97
Positive self-evaluation 0.97
I feel a sense of pride or accomplishment from surviving cancer 0.99
I consider myself to be a cancer survivor 0.96
I learned something about myself because of having had cancer 0.98
I feel that I am a role model 0.97
Appearance concerns 0.96
I feel disfigured 0.99
I sometimes wear clothing to cover parts of my body 0.98
I worry about how my body looks 0.98
Body change concerns 0.97
I am bothered that my body cannot do what it could before 0.99
I am concerned that my energy has not returned 0.99
Having had cancer has made me feel old. 0.99
Life interferences 0.88
Uncertainty about my future affects my decisions to make plans 0.34
Having had cancer has made me feel alone. 0.98
Having had cancer keeps me from doing activities I enjoy 0.58
I feel like cancer runs my life. 0.99
Having had cancer has made me feel that some people do not understand me 0.95
I feel guilty today for not having been available to my family 0.90
Ongoing symptoms interfere with my life. 0.95
Worry 0.98
Having had cancer makes me feel uncertain about my health 0.98
I worry about the future 0.97
Having had cancer makes me feel unsure about the future 0.97
I worry about cancer coming back 0.95
New symptoms make me worry about cancer coming back 0.97
I worry about my health 0.97
I feel like time in my life in running out 0.93
52 J Cancer Surviv (2010) 4:45–58Table 4 FACT, PCL-C, SF-36, PTGI, and Social Support scores in the NHL survivor sample and correlations (r) with IOCv2 scores on positive
scales
Instrument
a Mean
±SD
Positive impact
summary score
Positive subscales
Altruism/ Empathy Health awareness Meaning of cancer Positive self-evaluation
FACT-G (+)
Total 88±15 0.08 0.04 −0.02 0.07 0.15
Physical 24±5 −0.07 −0.09 −0.08 −0.06 0.01
Social/Family 23±5 0.19 0.21 0.07 0.13 0.20
Emotional 20±4 0.01 −0.03 −0.09 0.02 0.13
Functional 21±6 0.13 0.07 0.02 0.14 0.17
LYM 137±22 0.02 −0.01 −0.06 0.01 0.11
SF-36 (+)
Physical comp. 46±10 −0.01 −0.06 −0.01 0.01 0.03
Mental comp. 50±11 −0.00 −0.03 −0.06 0.01 0.08
SF-36 subscales
Physical funct. 45±12 −0.02 −0.06 0.01 −0.03 0.01
Role-physical 45±12 −0.01 −0.08 −0.03 0.02 0.03
Bodily pain 51±10 −0.02 −0.07 −0.02 −0.00 0.02
General health 46±11 0.02 −0.04 −0.05 0.05 0.08
Vitality 49±12 0.06 −0.01 −0.01 0.08 0.09
Social function. 49±11 0.00 −0.04 −0.04 0.02 0.06
Role-emotional 46±13 −0.04 −0.07 −0.05 −0.04 0.04
Mental health 50±10 −0.03 −0.05 −0.07 −0.02 0.05
PCL-C (−)
Total 26±9 0.07 0.08 0.12 0.05 −0.03
Re-experiencing 7±3 0.14 0.11 0.17 0.12 0.04
Avoidance 10±4 −0.01 0.01 0.09 −0.02 −0.11
Arousal 9±4 0.09 0.11 0.08 0.06 0.03
PTGI (+)
Total 62±24 0.75*** 0.64*** 0.45** 0.69*** 0.56**
Rel’ship w/others 23±9 0.67*** 0.62*** 0.38* 0.58** 0.53**
New possibilities 11±7 0.71*** 0.56** 0.41* 0.70*** 0.50**
Pers’l strength 12±5 0.67*** 0.55** 0.38* 0.65*** 0.51**
Spiritual change 6±3 0.60*** 0.55** 0.34* 0.53** 0.49**
Apprec. of life 10±4 0.68*** 0.56** 0.51** 0.59** 0.47**
Social support (+)
Total 84±16 0.10 0.09 0.02 0.07 0.14
Emotional/Info 81±18 0.09 0.07 0.01 0.07 0.12
Tangible 84±19 0.08 0.08 0.02 0.04 0.13
Affectionate 90±17 0.09 0.10 0.02 0.05 0.10
Pos. interaction 86±19 0.09 0.08 0.03 0.07 0.11
FACT Functional Assessment of Cancer Therapy; PCL-C Post-traumatic Stress Disorder Checklist-Civilian Version; PTGI Post-Traumatic Growth
Inventory.
*0.30≤|r|<0.45; **0.45≤|r|<0.60; ***|r|≥0.60; and P<0.005 for test that correlation equals zero.
a Instruments completed concurrently with the IOC. Direction of scoring is indicated in parentheses, with a negative (−) sign indicating that
higher scores correspond to poorer functioning and a positive (+) sign indicating that higher scores correspond to better functioning.
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scales
Instrument
a Negative impact
summary score
Negative subscales Employ
conc
Rel’ship conc:
not partnered
Rel’ship conc:
partnered
Appear
conc
Body chg
conc
Life
interfer
Worry
FACT-G (+)
Total −0.68*** −0.45** −0.60*** −0.59** −0.52** −0.45** −0.64*** −0.45**
Physical −0.59** −0.38* −0.65*** −0.52** −0.38* −0.36* −0.55** −0.28
Social/Family −0.39* −0.30* −0.27 −0.31* −0.34* −0.33* −0.42* −0.49**
Emotional −0.70*** −0.40* −0.50** −0.59** −0.63*** −0.38* −0.62*** −0.36*
Functional −0.53** −0.37* −0.51** −0.47** −0.38* −0.37* −0.45** −0.32*
LYM −0.73*** −0.47** −0.64*** −0.63*** −0.56** −0.48** −0.62*** −0.43*
SF-36 (+)
Physical comp. −0.30* −0.19 −0.41* −0.29 −0.15 −0.13 −0.04 −0.13
Mental comp. −0.53** −0.34* −0.47** −0.47** −0.41* −0.34* −0.54** −0.31*
SF-36 Subscales
Physical funct. −0.26 −0.15 −0.38* −0.28 −0.10 −0.12 −0.00 −0.13
Role-physical −0.35* −0.22 −0.46** −0.35* −0.17 −0.16 −0.19 −0.15
Bodily pain −0.35* −0.22 −0.37* −0.33* −0.22 −0.17 −0.19 −0.18
General health −0.52** −0.32* −0.50** −0.44* −0.41* −0.31* −0.32* −0.23
Vitality −0.50** −0.33* −0.55** −0.40* −0.36* −0.28 −0.37* −0.27
Social function. −0.44* −0.30* −0.42* −0.45** −0.28 −0.27 −0.34* −0.29
Role-emotional −0.41* −0.25 −0.45** −0.41* −0.25 −0.24 −0.36* −0.22
Mental health −0.53** −0.32* −0.44* −0.46** −0.44* −0.36* −0.49** −0.32*
PCL-C (−)
Total 0.70*** 0.41* 0.56** 0.63*** 0.57** 0.43* 0.59** 0.39*
Re-experiencing 0.54** 0.29 0.40* 0.51** 0.47** 0.37* 0.53** 0.22
Avoidance 0.66*** 0.39* 0.52** 0.61*** 0.54** 0.36* 0.63*** 0.42*
Arousal 0.59** 0.37* 0.51** 0.52** 0.47** 0.37* 0.39* 0.33*
PTGI (+)
Total 0.09 0.07 0.11 0.15 0.00 0.05 0.03 −0.10
Rel’ship w/others 0.07 0.04 0.12 0.13 −0.01 0.01 −0.03 −0.13
New possibilities 0.06 0.09 0.06 0.13 −0.02 0.09 0.08 −0.05
Pers’l strength 0.06 0.05 0.08 0.12 −0.02 0.04 −0.00 −0.08
Spiritual change 0.10 0.08 0.12 0.17 −0.01 0.06 0.04 −0.05
Apprec. of life 0.17 0.08 0.14 0.19 0.12 0.10 0.16 −0.11
Social Support (+)
Total −0.29 −0.25 −0.18 −0.26 −0.24 −0.29 −0.43* −0.41*
Emotional/Info −0.28 −0.18 −0.18 −0.27 −0.23 −0.26 −0.42* −0.34*
Tangible −0.20 −0.19 −0.11 −0.18 −0.17 −0.20 −0.31* −0.30*
Affectionate −0.20 −0.23 −0.10 −0.15 −0.17 −0.25 −0.28 −0.41*
Pos. interaction −0.26 −0.29 −.18 −0.22 −0.19 −0.28 −0.38* −0.41*
conc concerns; FACT Functional Assessment of Cancer Therapy; PCL-C Post-traumatic Stress Disorder Checklist-Civilian Version; PTGI Post-
Traumatic Growth Inventory.
*0.30≤|r|<0.45; **0.45≤|r|<0.60; *** |r|≥0.60; and P<0.005 for test that correlation equals zero.
aInstruments completed concurrently with the IOC. Direction of scoring is indicated in parentheses, with a negative (−) sign indicating that higher
scores correspond to poorer functioning and a positive (+) sign indicating that higher scores correspond to better functioning.
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There is a need for well-validated measures of the cancer-
specific HRQOL of long-term cancer survivors that can be
used across the spectrum of cancer diagnoses. Our study
was undertaken to examine the generalizability of the
IOCv2 across two distinct survivor groups. We compared
the measurement of the impact of cancer in large samples of
BC survivors and NHL survivors and found evidence for
similar impact domains across the two groups, providing
confidence that the IOCv2 scales measure common and
important survivor concerns.
Comparedtothe BCgroup,the NHLsurvivors represented
a broader range of time since diagnosis and ages at diagnosis,
as well as both genders, and came from a different geographic
areaoftheUS.Thegoodpsychometricpropertiesofthescales
in this distinct group, as well as the participation of diverse
samples of survivors in earlier stages of IOC development,
support the appropriateness of the IOCv2 as a tool to measure
the psychosocial impacts of cancer in the broader long-term
survivor population. However, some limitations in generaliz-
ability remain. While our NHL survivor sample included 151
participantswhoweresurvivorswithin2–5yearsofdiagnosis,
more work is needed to confirm that the IOCv2 items and
factor structure capture domains that are relevant to early
survivors, who are closer to the transition from patient to
survivor and thus may be experiencing different psychosocial
needs [7].
Some differences emerged in the independent scalings in
the BC and NHL samples. Content of the Life Interferences
domain differed somewhat across samples, and merged with
BodyChangeConcernsinNHLsurvivors.Consistentwiththis
is the high correlation between these two subscales in the BC
sample (r=0.6) [30]. Overall these findings suggest overlap
between these two domains. While the content of the Life
Interferences subscale was not fully congruent between the
BC and NHL survivors, the importance of a life interferences
domain for NHL survivors is supported by the study of
Bellizzi et al. [16], who report substantial proportions of NHL
survivors endorsing negative impacts on ability to participate
in social and exercise activities and to enjoy life as well as on
financial, career and insurance situations.
The Positive Outlook subscale, which emerged in early
IOC scaling with 193 survivors of breast, colorectal,
Table 6 Cronbach’s alpha statistics and unadjusted and adjusted mean IOCv2 scale scores for non-Hodgkin lymphoma and breast cancer survivor
samples
Scale Cronbach’s
alpha
Unadjusted means±SD (range) Adjusted means
BC NHL BC NHL P, NHL
vB C
BC NHL,
women only
NHL, men
and women
P, BC v NHL
women only
P, BC v NHL
men and women
Higher-order scales
Pos summary 0.79 0.90 3.6±0.6 (1.2–5) 3.5±0.8 (1–5) 0.04 3.6 3.7 3.5 0.22 0.09
Neg summary 0.81 0.91 2.4±0.7 (1–4.8) 2.1±0.7 (1–4.7) <0.001 2.4 2.2 2.2 0.007 <0.001
Pos. subscales
Altru/Empathy 0.82 0.87 3.8±0.7 (1–5) 3.9±0.9 (1–5) <0.001 3.7 4.1 3.9 <0.001 0.004
Health aware 0.80 0.71 3.8±0.7 (1–5) 3.7±0.8 (1–5) 0.01 3.8 3.8 3.7 0.94 0.26
Meaning of Ca 0.87 0.87 3.0±0.8 (1-5) 2.8±1.1 (1–5) <0.001 3.0 2.9 2.8 0.08 <0.001
Pos self-eval 0.79 0.77 4.0±0.7 (1–5) 4.0±0.9 (1–5) 0.86 4.0 4.1 3.9 0.14 0.20
Neg. subscales
Appear. conc 0.78 0.76 2.7±1.0 (1–5) 1.6±0.8 (1–5) <0.001 2.7 1.8 1.7 <0.001 <0.001
Body chg conc 0.82 0.83 2.6±1.0 (1–5) 2.3±1.2 (1–5) <0.001 2.5 2.5 2.5 0.66 0.54
Life interfer 0.81 0.71 1.9±0.6 (1–4.4) 1.9±0.7 (1–4.6) 0.90 1.9 1.9 2.0 0.46 0.17
Worry 0.89 0.89 2.8±0.8 (1–5) 2.5±1.0 (1–5) <0.001 2.7 2.6 2.6 0.17 0.09
Other subscales
Employ conc 0.76 0.75 2.7±1.1 (1–5) 2.4±1.2 (1–5) 0.002 2.7 2.4 2.5 0.12 0.27
Rel’ship conc
(not partnered)
0.78 0.59 2.1±0.9 (1–5) 1.6±0.9 (1–5) <0.001 2.0 1.5 1.7 0.004 0.03
Rel’ship conc
(partnered)
0.80 0.77 1.7±0.6 (1–4.5) 1.4±0.6 (1–3.5) <0.001 1.6 1.5 1.4 0.003 <0.001
BC breast cancer; NHL non-Hodgkin lymphoma.
For all scales, potential scores range from 1 to 5, with higher scores indicating stronger endorsement of the content area and with a score of 3 as
neutral. Adjusted means are adjusted for age and years since diagnosis.
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sample but was not evident in the large BC sample. The
sample used for early IOC scaling included 49 (25%)
lymphoma (Hodgkin and NHL) survivors, suggesting that
this domain might reflect concerns of this group that are not
as prevalent in BC survivors. Alternatively, the difference
may be due to the restriction of the BC sample to long-term
survivors who were within 10 years of their diagnosis; one
of the theoretical foundations of growth is sufficient time to
think about and integrate experiences into one’s life [50],
and the time interval may have been insufficient for some
of the BC survivors. Future research may explore the
universality of this construct and its association with time
since diagnosis.
We have also compared IOCv2 scores in NHL and BC
survivors. Normative and comparative scores across groups
will be important in facilitating interpretation and identifying
at-risk populations to target for intervention. Differences
between the NHL and BC groups for several domains,
including the Negative Impact Summary scale and Altruism/
Empathy, Meaning of Cancer, Appearance Concerns and
Relationship Concerns subscales, suggest that the IOCv2
scales are able to distinguish differential impacts in different
survivor groups. While it is beyond the scope of this paper to
fullyexploretheantecedentsofthesedifferences,wecanoffer
several observations. Subscale comparisons suggest that the
difference in Negative Impact Summary scores between the
BCandNHLgroupsmaybelargelyattributabletodifferences
on the Appearance Concerns subscale, with BC survivors
scoring about a full point higher on this domain. Body image
is a widely reported concern among BC survivors (e.g. [51,
52]). However, this should not be taken as evidence that
appearance concerns are exclusive to BC survivors, as such
concerns are also reported among survivors with other
diagnoses (e.g. [53–56]). Among perceived positive impacts
of cancer, the NHL survivors scored higher on Altruism/
Empathy while the BC survivors scored higher on Meaning
of Cancer. This may be interpreted as a difference in benefit-
finding domains in these two groups. There is a sizable
literature examining predictors of posttraumatic growth in
cancer survivors; within this literature, disease and treatment
characteristics have shown inconsistent associations with
posttraumatic growth [57]. To the extent that the IOCv2
identifies four distinct positive impact domains which may
be differentially associated with disease and treatment
characteristics, it may assist in providing greater differenti-
ation and clarity in this area in future research. We plan
future work to further characterize the perceived impact of
cancer in NHL survivors using the IOCv2 scales.
The higher order positive and negative summary scores
of the IOCv2 provide aggregate measures of impacts that
may be especially useful when data reduction is important.
However, as we saw with the positive scale scores in BC
and NHL survivors, groups can differ on subscales while
having little or no difference in summary scores. Hence we
would recommend that researchers using the IOCv2
examine both summary and subscale scores. Indeed, the
capability of eliciting different patterns of scores across
different survivor groups is an advantage of a multidimen-
sional measure such as the IOCv2.
Our study has several limitations. Respondents tended to
be older and were less racially/ethnically diverse than
nonrespondents in both groups, creating the potential for
response biases. Since our surveys were cross-sectional, we
were not able to evaluate test-retest reliability nor the ability
of the IOCv2 to measure change over time, which will be
important to assess in future research. In addition, the 47
items for the IOCv2 were selected based on data collected
via full administration of the 81-item IOC questionnaire. It
will be important to examine whether the domain and factor
structure of the IOCv2 holds up when the 47-item only
instrument is utilized in future studies. Work is also needed
to evaluate the IOCv2 in clinical settings, where it could be
used as a screening tool or to measure outcomes in a clinical
trial or program evaluation.
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